European Medicines Agency Commences Review of Oral Fixed-Dose Combination of Decitabine and Cedazuridine for the Treatment of Adults with Acute Myeloid Leukemia
PLEASANTON, Calif.–(BUSINESS WIRE)–Astex Pharmaceuticals, Inc. (Astex) today announce that the European Medicines Agency (EMA) has accepted the Marketing Authorisation Application (MAA) for the oral fixed-dose combination of decitabine and cedazuridine (ASTX727) for the initial treatment of adults with acute myeloid leukemia (AML) who are not candidates for standard induction chemotherapy. The current standard of care … [Read more…]
